Chord Therapeutics

Switzerland
Hasle, Lucerne, Switzerland

Company profile

Chord Therapeutics company profile

Chord Therapeutics is a clinical-stage pharmaceutical company developing drugs for patients with rare, life-threatening, and severely disabling diseases. The company is advancing its lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG). The company was founded in 2014 and based in Geneva, Switzerland.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2014-01-01, Year

Headquarters

Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
2
Total equity funding
$16M
Last funding
Series A / $16M / 2020-10-13
Last equity funding
Series A / $16M
Investors
2
Lead investors
2
Articles
6
Exited on
2021-12-20

Founders and investors

Lead investors

Eclosion SAOmega Funds

Investors

Eclosion SAOmega Funds